Literature DB >> 15172365

Oral manganese for liver imaging at three different field strengths.

Henrik S Thomsen1, Vibeke Loegager, Henrik Noergaard, Elizaveta Chabanova, Jakob M Moller, Jesper Sonne.   

Abstract

RATIONALE AND
OBJECTIVES: To study the magnetic resonance imaging signal intensity of the liver and gall bladder before and after ingestion of a new oral manganese containing contrast medium at three different field strengths.
MATERIALS AND METHODS: Twelve healthy male volunteers (mean age, 24.9 years; range, 20-39 years) underwent abdominal magnetic resonance imaging (T(2)W COR, T(1)W COR, T(1)W TRA) at 0.23 T, 0.6 T, and 1.5 T before and after the contrast administration. The duration of fasting was identical before the two studies. Volunteers were randomized into two equal groups (n = 6) to ingest either half or full strength CMC-001 providing either 0.8 or 1.6.g MnCl(2) plus absorption promoters. The CMC-001 dose was dissolved in 400 mL water and ingested 2.5 hours before imaging. The resulting images were evaluated with regard to visualization of the liver and the gall bladder by three radiologists. The signal intensity of the liver was also measured. Blood and urine samples were collected before and after ingestion of CMC-001.
RESULTS: The intake of CMC-001 caused a significant increase in the signal intensity of the liver at all three field strengths and at both dosages (up to 90%) on the T(1)W images. The internal structure of the liver was significantly better delineated. The bile in gall bladder was bright after ingestion of the low dose, but dark after the full dose. On the T(2)W images, CMC-001 lowered the signal intensity of liver with up to 30%. CMC-001 had a slight metallic taste, but of no importance according to the volunteers. No systematic adverse reactions caused by the contrast medium were registered. No changes in the blood levels of various routine parameters were measured.
CONCLUSION: It is possible to increase the signal intensity of the liver significantly by oral intake of essential nutritional elements including manganese. The imaging window is more than 2 hours.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15172365     DOI: 10.1016/j.acra.2004.01.004

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  6 in total

1.  Manganese chloride tetrahydrate (CMC-001) enhanced liver MRI: evaluation of efficacy and safety in healthy volunteers.

Authors:  Nils Albiin; Nikolaos Kartalis; Annika Bergquist; Bita Sadigh; Torkel B Brismar
Journal:  MAGMA       Date:  2012-03-08       Impact factor: 2.310

2.  MRI of colorectal cancer liver metastases: comparison of orally administered manganese with intravenously administered gadobenate dimeglumine.

Authors:  Torkel B Brismar; Nikolaos Kartalis; Christian Kylander; Nils Albiin
Journal:  Eur Radiol       Date:  2011-09-28       Impact factor: 5.315

Review 3.  Safety of MR liver specific contrast media.

Authors:  Marie-France Bellin; Judith A W Webb; Aart J Van Der Molen; Henrik S Thomsen; Sameh K Morcos
Journal:  Eur Radiol       Date:  2004-12-31       Impact factor: 5.315

4.  Initial clinical experience with oral manganese (CMC-001) for liver MR imaging.

Authors:  Henrik S Thomsen; Jelle O Barentsz; Flemming Burcharth; Elizaveta Chabanova; Helena M Dekker; Flemming Moesgaard; Jakob M Moller; Per Leth-Espensen; Vibeke Logager; Satoru Takahashi
Journal:  Eur Radiol       Date:  2006-06-09       Impact factor: 5.315

5.  Effect of new manganese contrast agent on tissue intensities in human volunteers: comparison of 0.23, 0.6 and 1.5 T MRI, a part of a phase I trial.

Authors:  E Chabanova; H S Thomsen; V Løgager; J M Moller; K Brage; K Fogh; J Bovin; J Elmig
Journal:  MAGMA       Date:  2004-07-16       Impact factor: 2.310

Review 6.  Contribution of metals to brain MR signal intensity: review articles.

Authors:  Tomonori Kanda; Yudai Nakai; Shuri Aoki; Hiroshi Oba; Keiko Toyoda; Kazuhiro Kitajima; Shigeru Furui
Journal:  Jpn J Radiol       Date:  2016-03-01       Impact factor: 2.374

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.